Pharmacological Therapy of COPD: Reasons for Optimism.

[1]  Ciro Casanova,et al.  The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. , 2011, American journal of respiratory and critical care medicine.

[2]  K. Rabe,et al.  From COPD to chronic systemic inflammatory syndrome? , 2007, The Lancet.

[3]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. , 2017, Respiratory medicine.

[4]  M. Cazzola,et al.  Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function , 2009, COPD.

[5]  M. Cazzola,et al.  A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.

[6]  J A Anderson,et al.  Adherence to inhaled therapy, mortality and hospital admission in COPD , 2009, Thorax.

[7]  B. Celli,et al.  Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. , 2014, Chest.

[8]  M. Decramer,et al.  Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey , 2002, European Respiratory Journal.

[9]  F. Martinez,et al.  Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction , 2017, American journal of respiratory and critical care medicine.

[10]  B. Celli.  Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details! , 2017, Archivos de bronconeumologia.

[11]  L. Fabbri,et al.  Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[12]  K. Rabe.  Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. , 2006, Proceedings of the American Thoracic Society.

[13]  B. Celli,et al.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[14]  Satoshi Konno,et al.  Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[15]  I. Gich,et al.  Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? , 2016, Chest.

[16]  H. Magnussen,et al.  Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD , 2015, European Respiratory Journal.

[17]  K. R. Chapman,et al.  Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[18]  H. Neffen,et al.  Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review. , 2012, Chest.

[19]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[20]  N. Anthonisen.  Lessons from the Lung Health Study. , 2004, Proceedings of the American Thoracic Society.

[21]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[22]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[23]  M. Cazzola,et al.  Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. , 2003, Respiratory medicine.

[24]  P. Chanez,et al.  Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial , 2007 .

[25]  Richard B. Reilly,et al.  Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease , 2017, American journal of respiratory and critical care medicine.

[26]  S. Keenan,et al.  Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure , 2017, European Respiratory Journal.

[27]  C. Crim,et al.  The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. , 2012, Chest.

[28]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[29]  F. Maltais,et al.  The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment. , 2004, Canadian respiratory journal.

[30]  J. Castro‐Rodriguez,et al.  Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. , 2012, Pulmonary pharmacology & therapeutics.

[31]  F. Martinez,et al.  Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk , 2018, American journal of respiratory and critical care medicine.

[32]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[33]  P. Laveneziana,et al.  The Clinical Importance of Dynamic Lung Hyperinflation in COPD , 2006, COPD.

[34]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[35]  A. Halayko,et al.  Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison , 2007, European Respiratory Journal.

[36]  S. Petersen,et al.  Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. , 2016, American journal of respiratory and critical care medicine.

[37]  P. Barnes.  The role of anticholinergics in chronic obstructive pulmonary disease. , 2004, The American journal of medicine.

[38]  Bartolome Celli,et al.  Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study , 2017, International journal of chronic obstructive pulmonary disease.

[39]  D. Price,et al.  The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes , 2016, International journal of chronic obstructive pulmonary disease.

[40]  S. Rennard,et al.  Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. , 2015, JAMA.

[41]  M. Nishimura,et al.  Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. , 2010, Respiratory medicine.

[42]  R. Casaburi,et al.  Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. , 2005, Chest.

[43]  J. Soriano,et al.  Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD , 2017, European Respiratory Journal.

[44]  R. Zuwallack,et al.  Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease. , 2004, The American journal of medicine.

[45]  M. Fine,et al.  Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. , 2014, JAMA.

[46]  B. Celli,et al.  Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. , 2006, Respiratory care.

[47]  K. Rabe,et al.  Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[48]  M. Cazzola.  Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. , 2009, Current opinion in investigational drugs.

[49]  Cotes Je,et al.  LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMA Report of the Medical Research Council Working Party , 1981, The Lancet.

[50]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[51]  Megan E. Piper,et al.  A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. , 2009, Archives of general psychiatry.

[52]  R. Buhl,et al.  Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age , 2016, International journal of chronic obstructive pulmonary disease.

[53]  Richard Casaburi,et al.  Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. , 2011, Respiratory medicine.

[54]  B. Celli,et al.  Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. , 2006, Chest.

[55]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[56]  D. O’Donnell,et al.  Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. , 2006, Journal of applied physiology.

[57]  B. Celli,et al.  Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. , 2014, Chest.

[58]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[59]  J. Soriano,et al.  Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. , 2015, Chest.

[60]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[61]  D. Sin,et al.  Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. , 2006, Proceedings of the American Thoracic Society.

[62]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[63]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[64]  E. Bateman,et al.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.

[65]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[66]  A. Church,et al.  Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.

[67]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[68]  L. Solberg,et al.  Smoking cessation strategies and evaluation. , 1988, Journal of the American College of Cardiology.

[69]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[70]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[71]  B. Make,et al.  Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients , 2012, International journal of chronic obstructive pulmonary disease.

[72]  J. Wedzicha,et al.  Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline , 2017, European Respiratory Journal.

[73]  I. Pavord,et al.  Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.

[74]  M. Decramer,et al.  Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial , 2005, The Lancet.

[75]  Thierry Troosters,et al.  COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention , 2008, COPD.

[76]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[77]  I. Pavord,et al.  Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[78]  G. Feldman,et al.  Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies , 2014, International journal of chronic obstructive pulmonary disease.

[79]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[80]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[81]  B. Celli,et al.  Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. , 2002, Chest.

[82]  H A Vrooman,et al.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.

[83]  H. Watz,et al.  Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.

[84]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[85]  E. Bateman,et al.  Roflumilast with long-acting &bgr;2-agonists for COPD: influence of exacerbation history , 2011, European Respiratory Journal.

[86]  Efficacy and safety profile of xanthines in COPD: a network meta-analysis , 2018, European Respiratory Review.

[87]  A. Anzueto,et al.  Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. , 2000, Chest.

[88]  J. Wedzicha,et al.  Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[89]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[90]  D. Mannino,et al.  International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.

[91]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[92]  D. Caillaud,et al.  Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD , 2017, International journal of chronic obstructive pulmonary disease.

[93]  P. Jones,et al.  Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations , 2003, European Respiratory Journal.

[94]  J. Wedzicha,et al.  Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. , 2018, The Lancet. Respiratory medicine.

[95]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[96]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[97]  N. Roche,et al.  Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.

[98]  L. Fabbri.  Benralizumab: for asthma, not yet for COPD. , 2014, The Lancet. Respiratory medicine.

[99]  Ciro Casanova,et al.  COPD comorbidities network , 2015, European Respiratory Journal.

[100]  O. Usmani,et al.  New Inhaler Devices - The Good, the Bad and the Ugly , 2014, Respiration.

[101]  D. Zamir,et al.  Inhaled budesonide therapy for patients with stable COPD. , 1995, Chest.

[102]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[103]  Sally J. Singh,et al.  Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. , 2016, Chest.

[104]  S. Spencer,et al.  Withdrawal from treatment as an outcome in the ISOLDE study of COPD. , 2003, Chest.

[105]  J. Walters,et al.  Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. , 2003, The Cochrane database of systematic reviews.

[106]  M. Tunks,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2008 update--highlights for primary care. , 2008, Canadian respiratory journal.

[107]  R. Zuwallack,et al.  Functional status and survival following pulmonary rehabilitation. , 2000, Chest.

[108]  Edwin K Silverman,et al.  Clinical practice. Alpha1-antitrypsin deficiency. , 2009, New England Journal of Medicine.

[109]  T. Seemungal,et al.  Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.

[110]  L. Aboussouan,et al.  Long-Acting Inhaled β2-Agonists for Stable COPD , 2003 .

[111]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[112]  E. Ford,et al.  Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. , 2015, Chest.

[113]  I. Pavord,et al.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.

[114]  M. Cazzola,et al.  New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol , 2013, Drug design, development and therapy.

[115]  M. Aubier,et al.  A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. , 1989, The New England journal of medicine.

[116]  R. Casaburi,et al.  Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. , 2011, Respiratory medicine.

[117]  H. Folgering,et al.  Pulmonary rehabilitation in chronic obstructive pulmonary disease. , 1998, The European respiratory journal.

[118]  B. Celli,et al.  A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. , 2003, Clinical therapeutics.

[119]  N. Zhong,et al.  Lung Function and Incidence of Chronic Obstructive Pulmonary Disease after Improved Cooking Fuels and Kitchen Ventilation: A 9-Year Prospective Cohort Study , 2014, PLoS medicine.

[120]  P. Lindenauer,et al.  Trends in mechanical ventilation among patients hospitalized with acute exacerbations of COPD in the United States, 2001 to 2011. , 2015, Chest.

[121]  E. Clini,et al.  Measures of dyspnea in pulmonary rehabilitation , 2010, Multidisciplinary respiratory medicine.

[122]  P. White.  Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD , 2014, Evidence-Based Medicine.

[123]  Y. Li,et al.  Tiotropium in Early‐Stage Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[124]  R. Rodríguez-Roisín,et al.  Disease progression in young patients with COPD: rethinking the Fletcher and Peto model , 2014, European Respiratory Journal.

[125]  F. Martinez,et al.  Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk , 2017, Heart.

[126]  A. Anzueto,et al.  Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.

[127]  Kay Tetzlaff,et al.  Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease , 2016, International journal of chronic obstructive pulmonary disease.

[128]  D. Mahler,et al.  Minimal important difference of the transition dyspnoea index in a multinational clinical trial , 2003, European Respiratory Journal.

[129]  R. Casaburi,et al.  Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. , 2004, The American journal of medicine.

[130]  B. Make.  How Can We Assess Outcomes of Clinical Trials: The MCID Approach , 2007, COPD.

[131]  P. Calverley,et al.  Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. , 2013, Chest.

[132]  F. Martinez,et al.  Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. , 2006, The Annals of thoracic surgery.

[133]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[134]  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. , 1980, Annals of internal medicine.

[135]  M. Stanbrook.  Prior use of inhaled corticosteroids was associated with less mortality in elders with COPD and pneumonia , 2012, Annals of Internal Medicine.

[136]  Alvar Agusti,et al.  Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. , 2015, Chest.

[137]  S. Suissa,et al.  Inhaled corticosteroids in COPD and the risk of serious pneumonia , 2013, Thorax.

[138]  R. Zuwallack,et al.  An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. , 2015, American journal of respiratory and critical care medicine.

[139]  T. Welte,et al.  Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[140]  J. Soriano,et al.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.

[141]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[142]  B. Celli,et al.  Benefits of Long‐Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three‐Year Follow‐up , 2017, American journal of respiratory and critical care medicine.

[143]  C. Jenkins,et al.  Cardiovascular events in patients with COPD: TORCH Study results , 2010, Thorax.

[144]  M. Cazzola,et al.  The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. , 2007, Respiratory medicine.

[145]  I. Pavord,et al.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.